Application of antagonist of integrin alpha M beta2 to preparation of medicine for treating blood platelet quantity related diseases

A technology of integrins and antagonists, which can be used in blood diseases, drug combinations, and extracellular fluid diseases, etc., can solve the problems of high price and short action time, and achieve the effect of low cost, strong specificity, and broad clinical application prospects

Inactive Publication Date: 2014-08-13
SUZHOU UNIV
View PDF2 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] The current therapeutic drugs are mainly hematopoietic factors thrombopoietin, interleukin-11, glucocorticoids for immune intervention, monoclonal antibodies, etc. However, each of the above-mentioned therapeutic drugs has its own limitations. RhTPO has potential side effects such as thrombosis, myelofibrosis, and venous blockage; intravenous immunoglobulin (IVIG) is suitable for refractory or urgently treated ITP patients, with mild side effects and unlimited use, but due to its action time Short, expensive, and limited clinical application (Beardsley DS, Ertem M. Platelet autoantibodies in immune thrombocytopenic purpura. Transfus Sci. 1998; 19:237-244)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of antagonist of integrin alpha M beta2 to preparation of medicine for treating blood platelet quantity related diseases
  • Application of antagonist of integrin alpha M beta2 to preparation of medicine for treating blood platelet quantity related diseases
  • Application of antagonist of integrin alpha M beta2 to preparation of medicine for treating blood platelet quantity related diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0032] Integrin α in the present invention Μ beta 2 The antagonists are well known in the industry, can be prepared according to known conventional methods, and can also be purchased commercially from Santa Cruz Corporation, and used in conventional methods.

[0033] The drug of the present invention can be only integrin alpha Μ beta 2 Antagonists that can also contain integrin alpha Μ beta 2 Composition of antagonists.

[0034] In general, drugs are available in various dosage forms, which may be taken orally or injected or applied topically.

[0035] Platelet count-related diseases in the present invention include primary or secondary thrombocytosis and primary or secondary thrombocytopenia, but are not limited to the above-mentioned diseases, and include all diseases caused by platelet count.

[0036] The inventors previously found that the binding of antibodies against the platelet membrane glycoprotein GPIb-IX-V to human platelets would lead to the aggregation of th...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of an antagonist of integrin alpha M beta2 to preparation of a medicine for treating blood platelet quantity related diseases. The blood platelet quantity related diseases include idiopathic or secondary thrombocytopenia and idiopathic or secondary thrombocytosis. The antagonist of the integrin alpha M beta2 can be an anti-integrin alpha M beta2 antibody, amino acid sequence polypeptide and oligopeptide of the integrin alpha M beta2, derivatives and analogues of the amino acid sequence polypeptide and oligopeptide of the integrin alpha M beta2, and a small-molecular compound antagonist of the integrin alpha M beta2. The invention discloses the application of the antagonist of the integrin alpha M beta2 to the preparation of the medicine for treating the blood platelet quantity related diseases for the first time.

Description

technical field [0001] The invention relates to the field of medicine, in particular to integrin alpha Μ beta 2 The application of the antagonist in the preparation of medicines for the treatment of diseases related to the number of platelets. Background technique [0002] Clinically, abnormal platelet counts caused by various factors can cause related diseases, such as primary or secondary thrombocytosis, primary or secondary thrombocytopenia, including immune thrombocytopenia, etc. Thrombocytosis is a myeloproliferative disorder characterized by abnormal hyperplasia of unknown cause accompanied by persistent increase of platelets. Thrombosis, splenomegaly, and platelet persistence increased significantly, and the etiology was unknown. The bleeding mechanism of this disease may be related to platelet dysfunction or enhanced fibrinolysis. According to the epidemiological survey of essential thrombocythemia in 5 European and American countries, the incidence rate is 0.59 / ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61K39/395A61P7/00A61P7/04
Inventor 戴克胜
Owner SUZHOU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap